Parathyroid hormone (PTH) assays able to distinguish between full-length PTH (PTH1-84) and N-terminally truncated PTH (PTH7-84) are of increasing significance in the accurate diagnosis of endocrine and osteological diseases. We describe the discovery of new N-terminal and C-terminal PTH variants and the development of selected reaction-monitoring (SRM)-based immunoassays specifically designed for the detection of full-length PTH [amino acid (aa)1-84] and 2 N-terminal variants, aa7-84 and aa34 -84.
Parathyroid hormone (PTH) 6 is produced in the parathyroid glands through the 2-step conversion of prepro-PTH (115 amino acids) to pro-PTH (90 amino acids) to the 84 amino acid peptide (PTH1-84). The hormone is secreted into the circulatory system to produce basal (healthy) concentrations of approximately 15-65 ng/L (1 ), and is assayed to assist in the diagnosis of hypo/hyperparathyroidism and hypercalcemia and in monitoring for renal osteodystrophy in patients with end-stage renal failure (1) (2) (3) . Conventional PTH assays typically rely on 2-antibody recognition systems coupled to a variety of detection modalities (4 -6 ) . Notably, the most specific assays are able to differentiate between different truncated forms of PTH and are referred to as second-and third-generation PTH assays (7, 8 ) .
Key to the application of these later-generation assays is the ability to selectively monitor various PTH forms of known biological consequence. In particular, 2 variants, full-length PTH1-84 and PTH missing the 6 N-terminal amino acids (PTH7-84), are the subject of increased clinical investigation and potential diagnostic capability. Because of the inability of existing assays to detect microheterogeneity (9 ) , these variants were historically considered as a single PTH value (i.e., the first-generation assays) (7 ) . The classification of each variant as its own molecular entity and the analysis and study of each independently suggest an antagonistic relationship between the 2 different forms in regard to calcium homeostasis (10 ) . In fact, there is mounting clinical evidence that the ratio between PTH1-84 and PTH7-84 may be used to differentiate between hyperparathyroid bone turnover and adynamic bone disease (11) (12) (13) .
The PTH1-84 -to-PTH7-84 paradigm is a recent example of the biological and clinical utility of microheterogeneity within the PTH protein. Indeed, other PTH variants were defined as far back as approximately 40 years ago. Perhaps the most mature of these, PTH1-34, has been identified as an in vivo variant that exhibits biochemical activity comparable to the full-length protein. Consequently, PTH1-34 is a classic example of a peptide-based bioactive variant that has transitioned through drug development to the point of US Food and Drug Administration clearance for the treatment of osteoporosis [rPTH1-34 (teriparatide)] ( 14 -16 ) . Collectively the routine monitoring of these clinically relevant PTH variants-PTH1-84, PTH7-84, and PTH1-34 -is achieved through 3 separate, highly specific immunometric assays. However, there are indications that even greater microheterogeneity exists within PTH, which has yet to be fully characterized to determine clinical utility and/or confounding effects on present-day assays. The accurate examination of known PTH variants and the simultaneous evaluation of other possible variants requires a degree of analytical freedom that universally escapes conventional assays. Here we describe mass spectrometric immunoassays (MSIA) that, although specifically designed for the detection of PTH1-84 and PTH7-84, also facilitate the simultaneous discovery and evaluation of further microheterogeneity in PTH.
Materials and Methods

APPROACH
As a starting point for the development of selected reaction-monitoring (SRM)-based assays for PTH, we surveyed the literature to define molecular variants already identified. In addition to the well-characterized truncated variants (e.g., PTH1-84 and PTH7-84), 4 other molecular versions have been reported in the literature as present in human biofluids (primarily plasma or serum). Aligning these fragments to the sequence of PTH1-84 produced a variant map revealing forms stemming predominantly from N-terminal truncations (Fig. 1A) . A conserved region (among several variants) was evident between residues 48 to 84. This region was suitable for immmunoaffinity targeting to capture ragged N-terminal variants (e.g., PTH1-84 and PTH7-84). We used a full-scan MSIA (MALDI-TOF MS) (17) (18) (19) (20) (21) (22) akin to the assay reported by Zhang et al. (23 ) to capture these variants and to discover other variants that were immunoreactive with the antibody (Fig. 1B) . Postcapture digestion of retained PTH (and variants) created the basis for SRM-MSIA (24 -28 ) , for which surrogate peptides representative of the different PTH variants were selected for analysis (Fig. 1C) .
REAGENTS
Goat polyclonal anti-PTH39 -84 antibody was purchased from Immutopics International. Recombinant human PTH (rhPTH) was obtained from Bachem. Premixed 2-[morpholino]ethanesulfonic acid-buffered saline powder packets were from Pierce. Extraction of PTH from plasma was carried out with proprietary MSIA pipette tips (MSIA-Tips) from Intrinsic Bioprobes derivatized with the PTH antibodies via 1,1Ј Carbonyldiimidazole chemistry as described below. Premade 10ϫ 0.1 mol/L HEPES-buffered saline buffer with 30 mmol/L EDTA and 0.2% (vol/vol) surfactant P20 (HBS-EP) was purchased from Biacore. Synthetic heavy-labeled peptides were obtained from ThermoFisher. All other chemicals were obtained from Sigma-Aldrich.
SAMPLES
All samples used in this study were acquired under an institutional review board-approved protocol, and informed consent was obtained from all study participants. A total of 24 serum samples, from 12 individuals with a diagnosis of severe renal impairment or endstage renal disease (10 males and 2 females; mean age 66.7 years) and 12 healthy individuals (10 males and 2 females; mean age 65 years) were used in the study. Of the patients with renal failure who donated samples, 3 were Hispanic, 2 were Asian, 2 were African American, and 6 were white. The ethnicity information for the healthy sample donors was not available. Calibration curves were prepared from pooled human plasma by step-wise, 2-fold serial dilution of an initial sample containing rhPTH at a concentration of 1000 ng/L (8 steps, range 1000 -7.8 ng/L). Samples were frozen at Ϫ80°C until use.
SAMPLE PREPARATION AND IMMUNOCAPTURE
MSIA-Tips were prepared by Intrinsic Bioprobes as previously described (17) (18) (19) (20) (21) (22) . Before analysis samples were thawed to 25°C in a water bath, and 1 mL of serum (or plasma) was diluted with 750 L HBS-EP buffer to a total analytical volume of 1.75 mL. PTH was then extracted with the aid of a Beckman Multimek 96 pipetting robot by repeatedly (1500 repetitions) drawing and expelling (back into the analytical volume) 125-L aliquots of the analytical volume through the antibody-prelinked MSIA-Tip. After extraction, the pipettes were rinsed with HBS-EP and H 2 O (in this order; each rinse ϭ 15 repetitions of 150 L), after which PTH was either immediately eluted for detection with MALDI-TOF MS or digested and analyzed with high-resolution liquid chromatography-tandem MS (LC-MS/MS) or SRM as described below. 
MALDI-TOF MASS SPECTROMETRY
0.4% (vol/vol) trifluoroacetic acid] into the pipette and depositing it onto a MALDI-TOF MS target (29 ).
We performed MALDI-TOF MS using a Bruker Ultraflex MALDI-TOF instrument operating in the positive ion, delayed-extraction mode; reflector engaged with ion source 1 at 25.00 kV, ion source 2 at 21.90 kV, lens at 9.50 kV, reflector at 26.30 kV, reflector 2 at 13.80, 340 ns delayed extraction, deflection signal suppression up to m/z 4000, and 2 GS/s sample rate. We signalaveraged 10 000 laser shots for each mass spectrum using a laser repetition rate of 100 Hz. Spectra were externally calibrated with a mixture of 4 proteins supplied by Bruker ranging in m/z from 5734.52 (insu-
ϩ ).
SAMPLE ELUTION AND TRYPSIN DIGESTION
Bound proteins were eluted from the tips into a 96-well plate (AB-1300, Abgene) by pipetting 100 L of 30% acetonitrile/0.5% formic acid up and down for a total of 15 cycles. Samples were lyophilized to dryness and then resuspended in 30 L of 30% n-propanol/100 mmol/L ammonium bicarbonate, pH 8.0, diluted with 100 L of 25 mmol/L acetic acid containing 100 ng of trypsin. Samples were allowed to digest for 4 h at 37°C. After digestion, samples were lyophilized and resuspended in 30 L of 3% (vol/vol) acetonitrile/0.2% (vol/ vol) formic acid/glucagon/PTH heavy peptides.
HIGH-RESOLUTION LC-MS/MS
High-resolution LC-MS/MS analysis was carried out on an LTQ-Orbitrap XL mass spectrometer (ThermoFisher Scientific). Samples in 5% (vol/vol) acetonitrile/0.1% (vol/vol) formic acid were injected onto a 75-m ϫ 25-cm fused silica capillary column packed with Hypersil Gold C18AQ 5-m media (ThermoFisher Scientific), in a 250 L/min gradient of 5% acetonitrile/0.1% formic acid to 30% acetonitrile/0.1% formic acid over the course of 180 min, with a total run length of 240 min and a flow rate of 285 nL/min. The LTQ-Orbitrap was run in a top 5 configuration at 60-K resolution for a full scan, with monoisotopic precursor selection enabled, and ϩ1 and unassigned charge state rejected. The analysis was carried out with collisioninduced dissociation and higher collision energy dissociation fragmentation modes.
SRM ASSAYS
SRM assays were developed on a TSQ Vantage triplequadrupole mass spectrometer, an Accela pump, a CTC PAL Autosampler, and an IonMax Source equipped with a high-flow metal needle (ThermoFisher Scientific). A mass window of full-width at half maximum of 0.7 (unit resolution) was used in the SRM assays because immunoenriched samples had a very high signal-to-noise. Narrower windows were necessary when the matrix background was significant and caused interferences in the SRM channels that reduced signal-to-noise. Reversed-phase separations were carried out on a 1-mm ϫ 100-mm Hypersil Gold 1.9-m C18 particle (ThermoFisher Scientific) with a flow rate of 160 L/min. Solvent A was 0.2% formic acid in LC-MS grade water, and solvent B was 0.2% formic acid in LC-MS grade acetonitrile (Optima grade reagents, ThermoFisher Scientific). Pinpoint software (ThermoFisher Scientific) was used for targeted protein quantification. The recently developed software algorithm automated the prediction of candidate peptides and the choice of multiple fragment ions for SRM assay design, as well as automating peptide identity confirmation and quantitative data processing. For the workflow described herein, the intact PTH sequence was imported into Pinpoint and digested with trypsin in silico, and then transitions for each peptide were predicted by use of the batch option in the software. This initial list of peptides and transitions (see Table 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/ content/vol56/issue2) was tested with recombinant PTH digest to determine those peptides and transitions delivering optimal signal. After several iterations, a subset of 6 peptides with multiple transitions was chosen (online Supplemental Table 2 contains the final list of peptides and transitions). Further assays were conducted with this optimized method. Once the target peptides were identified, heavy arginine or lysine versions were synthesized (ThermoFisher) to be used as internal quantitative standards. Target peptides were subsequently identified and quantified by coeluting light-and heavy-labeled transitions in the chromatographic separation. Time alignment and relative quantification of the transitions was performed with Pinpoint. All samples were assayed in triplicate.
Results
TOP-DOWN ANALYSIS AND DISCOVERY OF NOVEL VARIANTS
The approach described herein coupled targeting a common region of PTH by use of a polyclonal antibody (raised to the C-terminal end of the protein) with subsequent detection by use of MS (either MALDI-TOF MS or SRM). Using a top-down approach (MALDI-TOF MS), we discovered novel truncated PTH variants in clinical samples (Fig. 1) . The lower panel of Fig. 1 shows 2 MSIA (MALDI-TOF MS) spectra representative of those obtained from plasma samples of 12 individuals with renal failure and 12 healthy controls. Signals corresponding to the previously reported N-terminally truncated variants are indicated, as well as additional signals aligning with other novel variants. Notably, a conserved cleavage site (residue 77) was ob-served in several of these new variants (Fig. 1B) . With the exception of PTH7-84, the variants depicted in Fig.  1 , A and B, were detected in the majority of clinical samples and were not readily evident in the control samples ( Table 1) . As demonstrated in the top-down analysis described above, we were able to simultaneously extract numerous PTH variants with a single, high-affinity polyclonal antibody, and the selection of the epitope was directed by the desired assay target (i.e., intact and N-terminal variants). Our primary goal was to differentiate between intact PTH1-84 and N-terminal variant PTH7-84, while simultaneously identifying any additional N-terminal heterogeneity throughout the molecule. The results of these top-down experiments allowed the development of an initial standard profile for PTH. Clearly, this profile is not finite, and may be expanded to include additional variants found through literature search and/or complementary full-length studies. However, this standard profile provided an initial determination of target sequences for developing specific SRM assays.
SELECTION OF TRANSITIONS FOR SRM
During LC-MS/MS analysis, multiple charge states and fragmentation ions are generated from each fragment, resulting in upward of 1000 different precursor/product transitions possible for PTH digested with trypsin. Owing to time and cost restrictions, the empirical investigation of each transition was not efficient; therefore, a workflow incorporating predictive algorithms with iterative optimization was used to predict the optimal transitions for routine monitoring of tryptic fragments. The workflow we developed using Pinpoint for development of multiplexed SRM assays is shown in Fig. 2 . The strategy facilitated the translation of empirically obtained peptide intensity and fragmentation behavior from high-resolution LC-MS/MS to triplequadrupole MS SRM assays. Inherent to the success of the workflow was the similarity of peptide ion frag- mentation behavior in trap and triple-quadrupole instruments (30 ) . Empirical data from such LC-MS/MS experiments were used in conjunction with computational methods (e.g., in silico tryptic digestions and prediction of SRM transitions) to enhance the design of effective SRM assays for selected PTH peptides. Using this approach, we generated an initial list of transitions (online Supplemental Table 1 ) queried empirically to produce an LC-MS/MS profile initially based on 4 tryptic peptides that collectively spanned Ͼ50% of the full-length PTH sequence (45 of 84 amino acids). Of these, SVSEIQLMHNLGK [amino acid (aa)1-13] was monitored to represent PTH species with an intact N-terminus-i.e., PTH1-84. Other tryptic peptides, HLNSMER (aa14 -20), LDQVHN-FVALGAPLAPR (aa28 -44), and ADVNVLTK (aa73-80) were included for monitoring across the PTH sequence. In addition, transitions for 2 truncated tryptic peptides, LMHNLGK (aa7-13) and FVALGAPLAPR (aa34 -44), were added to the profile to monitor for truncated variants PTH7-84 and PTH34 -84, respectively. In summary, 32 SRM transitions tuned to these 6 peptides were used to monitor intact and variant forms of PTH (Fig. 1C and online Supplemental Table 2 ).
GENERATION OF STANDARD CURVES AND LIMITS OF DETECTION AND QUANTIFICATION
We used rhPTH spiked into stock human blood plasma to create calibration curves for all target tryptic peptides through serial dilution. As illustrated in Fig. 3 for peptides LQDVHNFVALGAPLAPR (aa28 -44) and SVSEIQLMHNLGK (aa1-13) respectively, SRM transitions for the 4 wild-type tryptic fragments exhibited linear responses (R 2 ϭ 0.90 -0.99) relative to rhPTH concentration, with limits of detection for intact PTH of 8 ng/L and limits of quantification for these peptides calculated at 31 and 16 ng/L, respectively. Standard error of analysis for all triplicate measurements in the 
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curves ranged from 3% to 12% for all peptides with Ͻ5% chromatographic drift between replicates. In addition, all experimental peptide measurements were calculated relative to heavy-labeled internal standards, and the CVs of integrated areas under the curve for 54 separate measurements (for each heavy peptide) ranged from 5% to 9%. Monitoring of variant SRM transitions showed no inflections relative to rhPTH concentration, as may be expected owing to the absence of truncated variants in the stock rhPTH.
EVALUATION OF CLINICAL SAMPLES
Initial SRM data were acquired from replicate plasma samples. Chromatograms for peptides SVSEIQLM-HNLGK (aa1-13), LQDVHNFVALGAPLAPR (aa28 -44), and LMHNLGK (aa7-13) are shown in online Supplemental Fig. 1 , A-C. Peak integration area and individual fragment transitions for both light and heavy peptides are illustrated. The light and heavy peptides coeluted precisely in all samples. Further SRM experiments were then carried out on the cohort of renal failure (n ϭ 12) and normal (n ϭ 12) clinical samples. Based on the MALDI-TOF MS data presented in Fig. 1 , bottom panel, and Table 1 , the most prominent PTH variant in the renal failure samples was PTH34 -84. To quantify this observation with SRM, we interrogated all samples to determine the expression ratios of renal failure to normal for the various target peptides, including FVALGAPLAPR (aa34 -84), which should be specific to the 34 -84 variant. Chromatographic data from single renal failure samples for peptides FVALGAPLAPR (aa34 -84) and SVSEIQLM-HNLGK (aa1-13) are shown in Fig. 4 . The peak integration area and individual coeluting fragment transitions for each peptide are illustrated. Similar chromatograms were obtained for peptides LQDVH-NFVALGAPLAPR (aa28 -44), HLNSMER (aa14 -20), and ADVNVLTK (aa73-80) (data not shown). The sample variances and expression ratios of renal failure to normal clinical samples for each peptide are shown in Fig. 5 . The expression ratios for the peptides ranged from 4.4 for FVALGAPLAPR (aa34 -84) to 12.3 for SVSEIQLMHNLGK (aa1-13). Online Supplemental Table 3 shows the absolute peptide concentrations. We did not detect notable quantities of peptide LMHN-LGK (aa 7-13) in these samples. Sample variances illustrated in the scatter plots in Fig. 5 demonstrate that the renal failure and normal samples groups were clearly segregated by the 5 target peptides.
Discussion
Many current clinical assays are based on the quantification of an analyte (protein) bound to an immobilized antibody and detected with another antibody labeled with a fluorophore, radioisotope, or reporter enzyme. For proteins of clinical interest, these techniques are limited by the ability of the antibodies to discriminate microheterogeneity in the target analytes, i.e., different molecular species that are very similar in structure. This limitation means that current assays do not capture the full information content of a target analyte (and its variants), which often results in ambiguities in the exact molecular species under investigation. Because upstream causes and downstream effects of disease are often due to such structural modifications, these limitations represent significant problems during the routine analysis of clinically significant analytes. A solution to this problem is to use mass spectrometry to accurately detect, identify, and quantify heterogeneous ligands captured by antibodies.
We developed an SRM-MSIA capable of simultaneously monitoring full-length PTH and truncated variants with analytical metrics suitable for clinical research use. The primary object of our investigations was the design of assays able to capture data on 2 of these species-PTH1-84 (intact) and PTH7-84 (an N-terminal variant). Through judicious choice of antibody, we eliminated potentially confounding data from PTH1-34 (because it was not captured and did not enter into the analysis). Using a workflow incorporating postcapture tryptic digestion, surrogate peptides representative of these 2 species were generated and monitored by using SRM. In addition, tryptic fragments spanning other regions of PTH were incorporated into the analysis. Relative ion signals for these species confirmed that the assay was functional and created the basis for a standard PTH profile. This standard profile was expanded to include a peptide representative of a novel clinical variant PTH34 -84, clipped at the N-terminus. In its present form, 32 SRM transitions are analyzed in a multiplexed assay to monitor nonvariant PTH sequences with Ͼ50% sequence coverage, as well as the 2 truncated variants. In further work, a systematic workflow allowed for the construction of an expandable variant map that presently contains an additional 8 molecular forms of PTH, including variants exhibiting conserved C-terminal truncations (i.e., truncations at PTH77). These newfound variants can be regarded in only 2 ways-as novel molecular forms of potential clinical value, or analytical nuisances that stand to confound PTH analysis. In either case, construction of assays responsive to such possibilities is critical to achieving the most accurate qualitative and quantitative definitions of PTH and its related variants.
